Guidance

Live attenuated influenza vaccine: responding to cold chain failures

How to handle live attenuated influenza vaccine (LAIV) (Fluenz Tetra®/Flumist®) stored outside the recommended temperature range.

From:
Public Health England
Published
21 October 2015

This publication was withdrawn on

This document on the thermo-stability of live attenuated influenza vaccine (LAIV) is no longer valid, following communication with the vaccine manufacturer. Immunisers should now follow the Summary of Product Characteristics.

Documents

Responding to cold chain failures involving the live attenuated influenza vaccine (LAIV) (Fluenz Tetra®/Flumist®)

Ref: PHE publications gateway number: 2015412

PDF, 291 KB, 5 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@phe.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This information sheet is to assist providers in taking prompt and appropriate action in the handling of live attenuated influenza vaccine (LAIV) (Fluenz Tetra®/Flumist®) that has been stored outside the recommended temperature range. This includes:

  • what to do if LAIV stock has been exposed to temperatures outside of those recommended for storage (2-8°C)
  • information on the stability of the the live attenuated intra-nasal influenza vaccine
  • an incident checklist for handling vaccine stock
Published 21 October 2015

Related content